Current bladder tumor tests: does their projected utility fulfill clinical necessity?

[1]  R. Day,et al.  Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  K Ito,et al.  Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations. , 2000, Urology.

[3]  M. Carducci,et al.  Management of patients with rising prostate-specific antigen after radical prostatectomy. , 2000, Urology.

[4]  A. Andersen,et al.  Cancer incidence and cause specific mortality among workers in two Norwegian aluminum reduction plants. , 2000, American journal of industrial medicine.

[5]  H. Grossman,et al.  Markers of bladder cancer State of the art. , 2000, Urologic oncology.

[6]  C. Öbek,et al.  Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. , 2000, The Journal of urology.

[7]  B. Konety,et al.  Use of urine-based markers for detection and monitoring of bladder cancer. , 1999, Techniques in urology.

[8]  T. Sun,et al.  Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. , 1999, The Journal of urology.

[9]  T. Chong,et al.  The role of the bladder tumour antigen test in the management of gross haematuria. , 1999, Singapore medical journal.

[10]  H. Biri,et al.  Comparison of the Nuclear Matrix Protein 22 with Voided Urine Cytology and BTA stat Test in the Diagnosis of Transitional Cell Carcinoma of the Bladder , 1999, European Urology.

[11]  A. Agarwal,et al.  NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. , 1999, Anticancer research.

[12]  M. Bibbo,et al.  Utility of the BTA stat test kit for bladder cancer screening , 1999, Diagnostic cytopathology.

[13]  P. Stieber,et al.  BTA-TRAK--a useful diagnostic tool in urinary bladder cancer? , 1999, Anticancer research.

[14]  A. K. Agarwal,et al.  Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. , 1999, The Journal of urology.

[15]  W. Murphy,et al.  Monitoring patients for bladder neoplasms: what can be expected of urinary cytology consultations in clinical practice. , 1999, Urology.

[16]  B. Konety,et al.  Diagnostic Value of Voided Urine and Bladder Barbotage Cytology in Detecting Transitional Cell Carcinoma of the Urinary Tract , 1999, Urologia Internationalis.

[17]  M. Marberger,et al.  Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. , 1999, The Journal of urology.

[18]  C. Dinney,et al.  Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional‐cell carcinoma of the bladder , 1999, Diagnostic cytopathology.

[19]  K Steenland,et al.  Cohort mortality study of 57,000 painters and other union members: a 15 year update. , 1999, Occupational and environmental medicine.

[20]  B. Konety,et al.  UTILIZATION OF THE BLADDER CANCER SPECIFIC NUCLEAR MATRIX PROTEIN: BLCA-4, FOR THE DETECTION OF BLADDER CANCER , 1999 .

[21]  K Koiso,et al.  Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria , 1999, International journal of urology : official journal of the Japanese Urological Association.

[22]  C. Sternberg,et al.  Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. , 1999, Clinical chemistry.

[23]  E. Crawford,et al.  Efficiency of prostate‐specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age‐specific reference range as a cutoff for abnormal values , 1999, The Prostate.

[24]  D J O'Kane,et al.  Comparison of screening methods in the detection of bladder cancer. , 1999, The Journal of urology.

[25]  D. Biasoni,et al.  Evaluation of Urinary Level of NMP22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test , 1999, European Urology.

[26]  J. Irani,et al.  BTA stat and BTA TRAK: A Comparative Evaluation of Urine Testing for the Diagnosis of Transitional Cell Carcinoma of the Bladder , 1999, European Urology.

[27]  M. Soloway.  Do we have a prostate specific antigen for bladder cancer? , 1999, The Journal of urology.

[28]  O. Nativ,et al.  Noninvasive detection of bladder cancer with the BTA stat test. , 1999, The Journal of urology.

[29]  J. Chang-Claude,et al.  Tobacco, occupation and non‐transitional‐cell carcinoma of the bladder: An international case‐control study , 1999, International journal of cancer.

[30]  U. Steiner,et al.  Quantitative Detection of Human Complement Factor H-Related Protein in Transitional Cell Carcinoma of the Urinary Bladder , 1999, European Urology.

[31]  C. Sternberg,et al.  Comparison of the BTA statTM Test with Voided Urine Cytology and Bladder Wash Cytology in the Diagnosis and Monitoring of Bladder Cancer , 1999, European Urology.

[32]  H. Grossman,et al.  Urothelial differentiation and bladder cancer. , 1999, Advances in experimental medicine and biology.

[33]  W. Ellis,et al.  The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. , 1999, The Journal of urology.

[34]  V. Serretta,et al.  Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. , 1999, Urology.

[35]  B. Liu,et al.  Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. , 1999, Urology.

[36]  O. Cussenot,et al.  Assessment of microsatellite instability in urine in the detection of transitional‐cell carcinoma of the bladder , 1998, International journal of cancer.

[37]  M. Droller.  EDITORIAL: MARKERS IN BLADDER CANCER-ISSUES TO CONSIDER , 1998 .

[38]  O. Kessler,et al.  Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? , 1998, The Journal of urology.

[39]  S. Kagawa,et al.  Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. , 1998, British journal of urology.

[40]  A. Edreira,et al.  Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy , 1998 .

[41]  R. Kinders,et al.  Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  R. Cote,et al.  Prognostic markers in bladder cancer: a contemporary review of the literature. , 1998, The Journal of urology.

[43]  M. Droller,et al.  Bladder cancer: State‐of‐the‐art care , 1998, CA: a cancer journal for clinicians.

[44]  M. Correale,et al.  Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. , 1998, Anticancer Research.

[45]  J. Shay,et al.  Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  S. Kyo,et al.  Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  M. Marberger,et al.  Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? , 1998, The Journal of urology.

[48]  M. Bibby,et al.  Telomerase activity in malignant and benign bladder conditions. , 1998, International journal of molecular medicine.

[49]  H. G. van der Poel,et al.  Urinary NMP22TM and Karyometry in the Diagnosis and Follow-Up of Patients with Superficial Bladder Cancer , 1998, European Urology.

[50]  S. C. Yang,et al.  Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  H. Saya,et al.  Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. , 1998, Journal of the National Cancer Institute.

[52]  M. Droller,et al.  Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity , 1998, Cancer.

[53]  H. G. van der Poel,et al.  Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. , 1998, Urology.

[54]  U. Norming,et al.  Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men. , 1998, Scandinavian journal of urology and nephrology.

[55]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[56]  W. Ellis,et al.  Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. , 1997, Urology.

[57]  M. Lundie,et al.  Rapid detection of bladder cancer: a comparative study of point of care tests. , 1997, The Journal of urology.

[58]  M. Pamplona,et al.  Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. , 1997, Urology.

[59]  Y. Fradet,et al.  Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark. , 1997, The Canadian journal of urology.

[60]  D. Lamm,et al.  A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. , 1997, Journal of Urology.

[61]  C. Cordon-Cardo,et al.  Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  C. Cordon-Cardo,et al.  Cigarette smoking and chromosome 9 alterations in bladder cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[63]  N. Block,et al.  Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. , 1997, Cancer research.

[64]  C. Öbek,et al.  Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. , 1997, Cancer research.

[65]  F. Ito,et al.  [Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels]. , 1997, Hinyokika kiyo. Acta urologica Japonica.

[66]  R. Ouellet-Hellstrom,et al.  Bladder cancer incidence in arylamine workers. , 1996, Journal of occupational and environmental medicine.

[67]  E. Messing,et al.  Bladder cancer screening. , 1996, Seminars in oncology.

[68]  D. Neal,et al.  Prognostic markers in bladder cancer , 1996 .

[69]  R. Molina,et al.  Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study. , 1996, European journal of cancer.

[70]  E. Crawford,et al.  Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. , 1996, Urology.

[71]  C. Greider,et al.  Telomere length regulation. , 1996, Annual review of biochemistry.

[72]  M. Zanon,et al.  Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. , 1996, The Journal of urology.

[73]  E. Messing,et al.  Hematuria home screening: repeat testing results. , 1995, The Journal of urology.

[74]  A. Verbeek,et al.  Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients , 1994 .

[75]  Wan Ariffin Bin Abdullah.  Singapore Med J , 1993 .

[76]  G. Vooijs,et al.  Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. , 1993, Acta cytologica.

[77]  A. Dowell,et al.  A community study of bladder cancer screening by the detection of occult urinary bleeding. , 1992, The Journal of urology.

[78]  N. Heney,et al.  Natural history of superficial bladder cancer. Prognostic features and long-term disease course. , 1992, The Urologic clinics of North America.

[79]  E. Messing,et al.  Home screening for hematuria: results of a multiclinic study. , 1992, The Journal of urology.

[80]  T. Igarashi,et al.  Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. , 1990, The Journal of urology.

[81]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[82]  D. Skinner,et al.  Diagnosis and Management of Genitourinary Cancer , 1987 .

[83]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[84]  G. Murphy,et al.  Further study of fibrinogen degradation products in bladder cancer detection. , 1978, Urology.

[85]  R. Galen,et al.  Beyond Normality: The Predictive Value and E ciency of Medical Diagnoses , 1975 .